Thoracoscopic Lobectomy Blooms in the VIOLET Trial.

Cornwell, Lorraine D; Ripley, Robert Taylor · NEJM Evid · 2022

rct · Level I

Where this comes from

Abstract

Thoracoscopic Lobectomy Blooms in the VIOLET TrialLung cancer is currently the deadliest malignancy worldwide. Societal stigma, poor survival rates, and comparatively low funding for lung cancer research all contribute to lingering therapeutic nihilism. But there are reasons for optimism. Recent advances in precision oncology with targeted therapies, immunotherapy, life-saving lung cancer screening efforts, and curative surgery for early stages are improving outcomes. The VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy (VIOLET) study, a large multicenter randomized controlled trial (RCT) by Lim et al. from the United Kingdom, reports the benefit of minimally invasive surgical resection with video-assisted thoracoscopic surgery (VATS) versus open thoracotomy for lung cancer.